Neurocrine Biosciences Reinstates Former CMO Amid Leadership Transition
Event summary
- Eiry W. Roberts, M.D., rejoins Neurocrine Biosciences as Chief Medical Officer, effective immediately, replacing Sanjay Keswani, M.D., who departs by mutual agreement.
- Roberts previously served as CMO from 2018 to 2025 and led key programs including INGREZZA® indication expansion and CRENESSITY® development.
- Roberts has 26 years of experience at Eli Lilly and currently serves on the Board of Directors of Bausch Health Companies.
- Neurocrine is advancing multiple late-stage programs and preparing for several important clinical milestones.
The big picture
Neurocrine Biosciences' reinstatement of Eiry W. Roberts as Chief Medical Officer underscores the company's focus on maintaining strategic continuity during a critical phase of clinical development. The move comes as Neurocrine advances multiple late-stage programs, highlighting the importance of experienced leadership in navigating regulatory milestones and commercializing its diverse portfolio of treatments for neurological, psychiatric, endocrine, and immunological disorders. Roberts' extensive background in research and development, coupled with her prior success at Neurocrine, positions her to drive the company's mission of relieving suffering for patients with unmet needs.
What we're watching
- Strategic Continuity
- How Roberts' deep knowledge of Neurocrine's pipeline and clinical development programs will impact the company's ability to meet upcoming milestones.
- Clinical Development
- Whether Neurocrine can sustain its late-stage program advancements under Roberts' leadership.
- Regulatory Milestones
- The pace at which Neurocrine can navigate FDA approvals for its robust pipeline of compounds.
